Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.

Isono, Makoto

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. [electronic resource] - Journal of experimental & clinical cancer research : CR 01 2017 - 1 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1756-9966

10.1186/s13046-016-0473-1 doi


Antimetabolites, Antineoplastic--pharmacology
Carcinoma, Transitional Cell--drug therapy
Caspases--metabolism
Cell Cycle--drug effects
Cell Line, Tumor
Cell Survival--drug effects
Checkpoint Kinase 1--genetics
Checkpoint Kinase 2--genetics
DNA Damage
Deoxycytidine--analogs & derivatives
Drug Screening Assays, Antitumor
Drug Synergism
Gene Expression Regulation, Neoplastic--drug effects
Humans
Poly(ADP-ribose) Polymerases--metabolism
Protein Kinase Inhibitors--pharmacology
RNA, Small Interfering
Thiophenes--pharmacology
Urea--analogs & derivatives
Urinary Bladder Neoplasms--drug therapy
Gemcitabine